BioCryst Announces FDA Approval of ORLADEYO (berotralstat), First Oral, Once-daily Therapy to Prevent Attacks in Hereditary Angioedema Patients

—Significant and sustained reduction in HAE attacks—

—Oral, once-daily prophylactic option
enables HAE patients to reduce burden of
therapy1 —

—ORLADEYO approved for adult and pediatric patients 12 years and older—

RESEARCH TRIANGLE PARK, N.C., Dec. 03, 2020 (GLOBE NEWSWIRE) — BioCryst
Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the U.S. Food and Drug